- Home
- FRPH vs CSTL Comparison
FRPH vs CSTL Comparison
Compare FRPH & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRPH
- CSTL
- Stock Information
- Founded
- FRPH 1986
- CSTL 2007
- Country
- FRPH United States
- CSTL United States
- Employees
- FRPH N/A
- CSTL N/A
- Industry
- FRPH Real Estate
- CSTL Medical Specialities
- Sector
- FRPH Finance
- CSTL Health Care
- Exchange
- FRPH Nasdaq
- CSTL Nasdaq
- Market Cap
- FRPH 519.9M
- CSTL 561.9M
- IPO Year
- FRPH N/A
- CSTL 2019
- Fundamental
- Price
- FRPH $27.22
- CSTL $16.07
- Analyst Decision
- FRPH
- CSTL Strong Buy
- Analyst Count
- FRPH 0
- CSTL 6
- Target Price
- FRPH N/A
- CSTL $37.67
- AVG Volume (30 Days)
- FRPH 52.4K
- CSTL 423.5K
- Earning Date
- FRPH 08-06-2025
- CSTL 08-04-2025
- Dividend Yield
- FRPH N/A
- CSTL N/A
- EPS Growth
- FRPH 12.32
- CSTL N/A
- EPS
- FRPH 0.36
- CSTL N/A
- Revenue
- FRPH $31,576,000.00
- CSTL $347,083,000.00
- Revenue This Year
- FRPH N/A
- CSTL N/A
- Revenue Next Year
- FRPH N/A
- CSTL $1.36
- P/E Ratio
- FRPH $75.74
- CSTL N/A
- Revenue Growth
- FRPH 4.58
- CSTL 38.43
- 52 Week Low
- FRPH $25.37
- CSTL $15.45
- 52 Week High
- FRPH $33.00
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- FRPH 51.48
- CSTL 31.25
- Support Level
- FRPH $27.20
- CSTL $16.16
- Resistance Level
- FRPH $27.26
- CSTL $17.31
- Average True Range (ATR)
- FRPH 0.48
- CSTL 0.79
- MACD
- FRPH 0.04
- CSTL -0.40
- Stochastic Oscillator
- FRPH 70.83
- CSTL 1.64
About FRPH FRP Holdings Inc.
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.